Related references
Note: Only part of the references are listed.Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Ashley Hamilton et al.
BLOOD (2012)
HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells
Haojian Zhang et al.
BLOOD (2012)
Scd1 Plays a Tumor-Suppressive Role in Survival of Leukemia Stem Cells and the Development of Chronic Myeloid Leukemia
Haojian Zhang et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells
Haojian Zhang et al.
NATURE GENETICS (2012)
A PML-PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance
Keisuke Ito et al.
NATURE MEDICINE (2012)
The role of stearoyl-CoA desaturase in obesity, insulin resistance, and inflammation
Harini Sampath et al.
YEAR IN DIABETES AND OBESITY (2011)
IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development
Damien Reynaud et al.
CANCER CELL (2011)
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
Wayne W. Chan et al.
CANCER CELL (2011)
Targeting HIF1α Eliminates Cancer Stem Cells in Hematological Malignancies
Yin Wang et al.
CELL STEM CELL (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
Christian Hurtz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition
Cihangir Duy et al.
NATURE (2011)
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice
Cong Peng et al.
BLOOD (2010)
Hematopoietic stem cell function requires 12/15-lipoxygenase-dependent fatty acid metabolism
Michelle Kinder et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
BCL6 is critical for the development of a diverse primary B cell repertoire
Cihangir Duy et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Knock down of HIF-1α in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres
Olga Mendez et al.
MOLECULAR CANCER (2010)
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia
Y. Chen et al.
LEUKEMIA (2010)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Kazuhito Naka et al.
NATURE (2010)
Inhibition of StearoylCoA Desaturase Activity Blocks Cell Cycle Progression and Induces Programmed Cell Death in Lung Cancer Cells
Daniel Hess et al.
PLOS ONE (2010)
Identification of a Cell of Origin for Human Prostate Cancer
Andrew S. Goldstein et al.
SCIENCE (2010)
Molecular and cellular bases of chronic myeloid leukemia
Yaoyu Chen et al.
PROTEIN & CELL (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Chen Zhao et al.
NATURE (2009)
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
Yaoyu Chen et al.
NATURE GENETICS (2009)
Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α
A. Soeda et al.
ONCOGENE (2009)
Inhibition of StearoylCoA Desaturase-1 Inactivates Acetyl-CoA Carboxylase and Impairs Proliferation in Cancer Cells: Role of AMPK
Natalia Scaglia et al.
PLOS ONE (2009)
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
Ji Wu et al.
BLOOD (2008)
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation
Christine Dierks et al.
CANCER CELL (2008)
Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells
Heiko Konig et al.
CANCER RESEARCH (2008)
The role of oxygen availability in embryonic development and stem cell function
M. Celeste Simon et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Getting to the stem of chronic myeloid leukaemia
Michael Savona et al.
NATURE REVIEWS CANCER (2008)
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Jane E. Visvader et al.
NATURE REVIEWS CANCER (2008)
Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo
Chen Zhao et al.
CANCER CELL (2007)
Flying under the radar:: the new wave of BCR-ABL inhibitors
Alfonso Quintas-Cardama et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
Oliver Ottmann et al.
BLOOD (2007)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Junia V. Melo et al.
NATURE REVIEWS CANCER (2007)
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot et al.
BLOOD (2007)
Hypoxia-inducible factors, stem cells, and cancer
Brian Keith et al.
CELL (2007)
Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice
Jessica B. Flowers et al.
DIABETES (2007)
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
Jorge Cortes et al.
BLOOD (2007)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus et al.
BLOOD (2007)
Identification of pancreatic cancer stem cells
Chenwei Li et al.
CANCER RESEARCH (2007)
Identification and expansion of human colon-cancer-initiating cells
Lucia Ricci-Vitiani et al.
NATURE (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice
Yiguo Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Allosteric inhibitors of Bcr-abl-dependent cell proliferation
FJ Adrián et al.
NATURE CHEMICAL BIOLOGY (2006)
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph plus chronic myeloid leukemia patients
RG Piazza et al.
LEUKEMIA (2005)
Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells
N Scaglia et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Identification of bronchioalveolar stem cells in normal lung and lung cancer
CFB Kim et al.
CELL (2005)
Leukaemia stem cells and the evolution of cancer-stem-cell research
BJP Huntly et al.
NATURE REVIEWS CANCER (2005)
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
R Ren
NATURE REVIEWS CANCER (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Cancer stem cells: lessons from leukemia
JCY Wang et al.
TRENDS IN CELL BIOLOGY (2005)
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
YG Hu et al.
NATURE GENETICS (2004)
To the editor: Discontinuation of imatinib therapy after achieving a molecular response
J Cortes et al.
BLOOD (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells
RT Phan et al.
NATURE (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
BJP Huntly et al.
CANCER CELL (2004)
The BCR-ABL story: Bench to bedside and back
S Wong et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle
SM Rahman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
R Bhatia et al.
BLOOD (2003)
Recent insights into stearoyl-CoA desaturase-1
JM Ntambi et al.
CURRENT OPINION IN LIPIDOLOGY (2003)
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells
IK Park et al.
NATURE (2003)
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells
J Lessard et al.
NATURE (2003)
Prospective identification of tumorigenic breast cancer cells
M Al-Hajj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Essential role of Src-family protein tyrosine kinases in NF-κB activation during B cell development
K Saijo et al.
NATURE IMMUNOLOGY (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin
M Mayerhofer et al.
BLOOD (2002)
Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats
FS Falvella et al.
CARCINOGENESIS (2002)
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90
ME Gorre et al.
BLOOD (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role of Lyn in the myeloid lineage
KW Harder et al.
IMMUNITY (2001)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
The B-cell-specific src-family kinase Blk is dispensable for B-cell development and activation
G Texido et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: Roles for phosphatidylinositol 3-kinase and Raf
MS Neshat et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
